N@N

Affymax to Webcast Analyst Briefing on Hematidea"/Peginesatide Development Program

_{//health-fitness.news-articles.net/content/2010/ .. -hematidea-peginesatide-development-program.html}
^{Published in Health and Fitness on Tuesday, November 23rd 2010 at 5:05 GMT by Market Wire}  

PALO ALTO, Calif.--([ BUSINESS WIRE ])--Affymax, Inc. (NASDAQ:AFFY) today announced it will host an analyst briefing on Thursday, December 2, 2010 at 9:00 a.m. ET.

Affymax management will provide clinical, regulatory and commercial updates on Hematidea"/peginesatide. There will also be a featured presentation by Dr. Steven Fishbane, lead investigator on the Phase 3 program and chief medical officer of Winthrop-University Hospital and chief of the division of Nephrology and medical director of Winthropa™s Dialysis Network.

The live webcast, to begin at 9:00 a.m. ET, may be accessed from the investors section of the company's website at [ www.affymax.com ]. A replay will also be available for 30 days following the presentation.

About Hematidea"/peginesatide

Peginesatide is a novel investigational synthetic, PEGylated peptidic compound that binds to and activates the erythropoietin receptor and thus acts as an ESA.

Affymax and Takeda are collaborating on the development of peginesatide and plan to co-commercialize the product once approved in the United States. Phase 3 clinical trials investigated the potential for peginesatide to treat anemia associated with chronic renal failure. The product, upon approval, will be commercialized outside the United States by Takeda.

About Affymax, Inc.

Affymax, Inc. is a biopharmaceutical company committed to developing novel drugs to improve the treatment of serious and often life-threatening conditions. For additional information, please visit [ www.affymax.com ].